This research varies from other analyses in using a product-level, rather than a macro, approach.
PharmacoEconomics has just published OHE’s study projecting medicines expenditure in the UK to 2015. ( The methodology for this research varies from earlier approaches in using a product-level, or “bottom-up”, approach, rather than a top-down, macro perspective.
Four papers presented at the EuroQol Plenary discussed preliminary findings.
As reported earlier, OHE’s Prof Nancy Devlin and Prof Ben van Hout of the University of Sheffield were awarded a £457,000 grant from the Policy Research Programme (PRP) of the UK’s National Institute for Health Research (NIHR) for research on an EQ-5D-5L value set for England.
At an OHE seminar last week, Dr James Chambers of Tufts Medical School examined the role cost-effectiveness evidence plays in health care resource allocation in the US and the potential value of expanding that.
Following allegations of seriously substandard care, the Secretary of State for Health in England announced, in June 2010, that a public inquiry into the Mid Staffordshire NHS Foundation Trust would be undertaken, chaired by Robert Francis QC (a lawyer). The “Francis report”, issued in February 2013, contains 290 recommendations meant to apply across the NHS. This, in turn, has given rise to heated debates about quality in the NHS and how best to ensure it.
Professor Adrian Towse, OHE’s Director, joined Professor Sir John Bell and Professor Andrew Morris at the Science Media Centre last week to launch Realising the Potential of Stratified Medicine, a new report by the UK’s Academy of Medical Sciences. Adrian and Professor Lou Garrison, OHE Visiting Senior Research Fellow, were two of a dozen experts who oversaw the preparation of the report.
A new publication from the Office of Health Economics captures the views of thought leaders from around the world about the scientific and economic climate for drug development by 2022. Based on OHE’s 50th anniversary conference, it reflects the perspectives of payers, regulatory and HTA agencies, academia, the non-profit sector and the biopharmaceutical industry.
The Health Economists’ Study Group (HESG) was founded in 1972 to support and promote the work of health economists. Its members are from academic, commercial, and government settings. The purpose of HESG is to transmit knowledge and ideas, ranging from the theoretical to very practical policy issues.
OHE’s participation at the 33rd Meeting of the Spanish Health Economics Association (AES) last week reported the results of four research projects. Jorge Mestre-Ferrandiz, OHE’s Director of Consulting, presented OHE’s recent research on projecting medicines expenditures in the NHS using a bottom-up, rather than a top-down, approach.
In this video, Adrian Towse discusses the challenges and importance of appropriately valuing genomic medicine. He addresses both gene therapies and “pharmacogenomics” -- those medicines that will allow targeted, precision treatment.